Imidazo [4,5-C]quinoline derivatives and their use in the treatment of tumors and/or inflammation

1. A compound of formula (I),

wherein

R 1 is phenyl substituted with —C(CH 3 ) 2 CN;

R 2 is alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or —NHR 8 ;

R 3 , R 4 , R 5 and R 7 are hydrogen;

R 6 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, halogen, acyl, hydroxy, amino, cyano, nitro, thiol, —COOH, —CONH 2 , —OR 8 , —NHR 8 , —SR 8 or —B(OH) 2 ;

R 8 at each occurrence is independently selected from alkyl, alkenyl, aralkyl or aryl; and

Y is —C(O), —C(S) or —S(O) 2 ;

wherein,

alkyl is unsubstituted or substituted with one or more of the same or different groups selected from halogen, nitro, cyano, amino, hydroxy, alkoxy, acyl, —CONH 2 , or aryl;

alkenyl is unsubstituted or substituted with one or more of the same or different groups selected from alkyl, halogen, hydroxy, cyano, nitro, acyl, haloalkyl, alkoxy or aryl;

alkynyl is unsubstituted or substituted with one or more of the same or different groups selected from alkyl, halogen, hydroxy, cyano, nitro, acyl, haloalkyl, alkoxy or aryl;

cycloalkyl is unsubstituted or substituted with one or more of the same or different groups selected from halogen, nitro, cyano, amino, hydroxy, alkyl, alkoxy, haloalkyl, acyl, —CONH 2 or aryl;

aryl is unsubstituted or substituted with one or more of the same or different groups selected from cyano, nitro, halogen, alkyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, acyl or aryl;

heteroaryl is unsubstituted or substituted with one or more of the same or different groups selected from cyano, nitro, alkyl, haloalkyl, alkoxy, hydroxy, halogen, amino, —CONH 2 , carboxy, acyl or aryl;

heterocyclyl is unsubstituted or substituted with one or more of the same or different groups selected from cyano, nitro, halogen, alkyl, haloalkyl, hydroxy, alkoxy, amino, —CONH 2 , carboxy, acyl or aryl; or

a stereoisomer, a tautomer, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof.

2. A compound according to claim 1 , wherein R 6 is halogen or alkyl; or a stereoisomer, a tautomer, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof.

3. A compound according to claim 1 , wherein Y is —S(O) 2 ; or a stereoisomer, a tautomer, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof.

4. A compound according to claim 1 , wherein Y is —C(O); or a stereoisomer, a tautomer, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof.

5. A compound according to claim 1 , wherein R 2 is —NHR 8 , wherein R 8 is alkyl, alkenyl, aralkyl or aryl; a stereoisomer, a tautomer, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof.

6. A compound according to claim 1 selected from:

2-(4-(8-bromo-2-oxo-3-(4-(trifluoromethoxy)phenylsulfonyl)-2,3-dihydro-1H-imidazo [4,5-c]quinolin-1-yl) phenyl)-2-methylpropanenitrile;

2-(8-bromo-1-(4-(2-cyanopropan-2-yl)phenyl)-2-oxo-1H-imidazo[4,5-c]quinolin-3(2H)-ylsulfonyl)benzonitrile;

2-(4-(8-bromo-2-oxo-3-(m-tolylsulfonyI)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl) phenyl)-2-methylpropanenitrile;

2-(4-(8-bromo-3-(2-methyl-4-nitrophenylsulfonyl)-2-oxo-2,3-dihydro-1H-imidazo [4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile;

2-(4-(8-bromo-3-(3-fluoro-4-methylphenylsulfonyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile;

2-(4-(8-bromo-3-(3,5-dimethylphenylsulfonyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile;

2-(4-(8-bromo-2-oxo-3-(phenylsulfonyl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl) phenyl)-2-methylpropanenitrile;

2-(4-(8-bromo-2-oxo-3-tosyl-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile;

2-(4-(8-bromo-2-oxo-3-(thiophen-2-ylsulfonyl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile;

2-(4-(8-bromo-3-(3-fluorophenylsulfonyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile;

2-(4-(8-bromo-2-oxo-3-(quinolin-8-ylsulfonyl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile;

2-(4-(3-(4-acetylphenylsulfonyl)-8-bromo-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile;

2-(4-(8-bromo-2-oxo-3-(3-(trifluoromethyl)phenylsulfonyl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile;

2-(4-(8-bromo-3-(3-methoxyphenylsulfonyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile;

2-(4-(8-bromo-3-(3-bromophenylsulfonyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile;

2-(4-(8-bromo-3-(3,5-difluorophenylsulfonyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile;

2-(4-(8-bromo-3-(2,4-difluorophenylsulfonyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile;

2-(4-(8-bromo-3-(methylsulfonyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl) phenyl)-2-methylpropanenitrile;

2-(4-(8-chloro-2-oxo-3-(m-tolylsulfonyl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl) phenyl)-2-methylpropanenitrile;

2-(8-chloro-1-(4-(2-cyanopropan-2-yl)phenyl)-2-oxo-1H-imidazo[4,5-c]quinolin-3(2H)-ylsulfonyl)benzonitrile;

2-methyl-2-(4-(8-methyl-2-oxo-3-(m-tolylsulfonyl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile;

2-(4-(3-(3-fluorophenylsulfonyl)-8-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile;

2-methyl-2-(4-(8-methyl-3-(2-methyl-5-nitrophenylsulfonyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile;

2-methyl-2-(4-(8-methyl-2-oxo-3-(quinolin-8-ylsulfonyl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile;

2-(4-(3-(4-acetylphenylsulfonyl)-8-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin -1-yl)phenyl)-2-methylpropanenitrile;

2-(4-(8-bromo-3-(morpholine-4-carbonyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile;

(E)-2-(4-(8-bromo-3-but-2-cnoyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl) phenyl)-2-methylpropanenitrile;

2-(4-(8-bromo-2-oxo-3-(2-propylpentanoyl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl) phenyl)-2-methylpropanenitrile;

(E)-2-(4-(8-bromo-3-cinnamoyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl) phenyl)-2-methylpropanenitrile;

2-(4-(3-benzoyl-8-bromo-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile;

8-bromo-1-(4-(2-cyanopropan-2-yl)phenyl)-N-(4-methoxyphenyl)-2-oxo-1H-imidazo [4,5-c]quinoline-3(2H)-carboxamide;

N-benzyl-8-bromo-1-(4-(2-cyanopropan-2-yl)phenyl)-2-oxo-1H-imidazo[4,5-c]quinoline-3(2H)-carboxamide;

8-Bromo-N-(2-bromophenyl)-1-(4-(2-cyanopropan-2-yl)phenyl)-2-oxo-1H-imidazo[4,5-c]quinoline-3(2H)-carboxamide;

8-bromo-N-(2-chloroethyl)-1-(4-(2-cyanopropan-2-yl)phenyl)-2-oxo-1H-imidazo[4,5-c]quinoline-3(2H)-carboxamide;

N-allyl-8-bromo-1-(4-(2-cyanopropan-2-yl)phenyl)-2-oxo-1H-imidazo[4,5-c]quinoline-3(2H)-carboxamide;

2-(4-(3-acetyl-8-chloro-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-l-yl)phenyl)-2-methylpropanenitrile;

2-(4-(3-benzoyl-8-chloro-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile;

(E)-2-(4-(3-but-2-enoyl-8-chloro-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl) phenyl)-2-methylpropanenitrile;

(E)-2-(4-(3-but-2-enoyl-8-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin- 1 -yl) phenyl)-2-methylpropanenitrile; and

8-bromo-N-(2-chloroethyl)-1-(4-(2-cyanopropan-2-yl)phenyl)-2-oxo-1H-imidazo[4,5-c]quinoline-3(2H)-carbothioamide; or

a stereoisomer, a tautomer, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof.

7. A pharmaceutical composition, comprising a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof and a pharmaceutically acceptable excipient or carrier.

8. A method for the treatment of diseases mediated by PI3K or mTOR, wherein the disease is cancer and the cancer is selected from the group consisting of small-cell lung cancer, non-small-cell lung cancer, prostate cancer, ovarian cancer, colorectal cancer, pancreatic cancer, breast cancer and glioblastoma comprising administering to a mammal in need thereof, a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof.

9. A method for the treatment of disorders mediated by TNF-αor IL-6, wherein the TNF-α, mediated disorder or IL-6 related disorder is selected from the group consisting of rheumatoid arthritis, Crohn's disease, ulcerative colitis, septic shock, psoriasis and atherosclerosis comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof.

10. A process for the preparation of a compound of formula (A 8)

wherein, R 2 is alkyl, alkenyl, aryl, heterocyclyl or heteroaryl, R 3 is hydrogen, R 1 , R 4 , R 5 , R 6 , and R 7 are as defined for formula (I) according to claim 1 , which comprises:

reacting a compound of formula (A7)

with a compound of formula R 2 COCl , wherein R 2 is alkyl, alkenyl, aryl, heterocyclyl or heteroaryl, R 3 is hydrogen, R 1 , R 4 , R 5 , R 6 , and R 7 are as defined for formula (I) according to claim 1 , in the presence of sodium hydride as the base and dimethylformamide (DMF) as the solvent to obtain the compound of formula (A8); and optionally converting the resulting compound into a pharmaceutically acceptable salt.

11. A process for the preparation of a compound of formula (A 9)

wherein, R 3 is hydrogen; R 1 , R 2 , R 4 , R 5 , R 6 and R 7 are as defined for formula (I), according to claim 1 , which comprises:

reacting a compound of formula (A7)

with a compound of formula R 2 SO 2 Cl, R 3 is hydrogen; R 1 , R 2 , R 4 , R 5 , R 6 and R 7 are as defined for formula (I), according to claim 1 in the presence of triethylamine as the base to obtain the compound of formula (A9); and optionally converting the resulting compound into a pharmaceutically acceptable salt.

12. A process for the preparation of a compound of formula (A 10)

wherein, R 3 is hydrogen; R 1 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined for formula (I), according to claim 1 , which comprises:

reacting a compound of formula (A7)

with a compound of formula R 8 N═C═O, wherein R 3 is hydrogen; R 1 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined for formula (I), according to claim 1 in the presence of benzene or dichloromethane (DCM) as a solvent to obtain the compound of formula (A 10); and optionally converting the resulting compound into a pharmaceutically acceptable salt.

13. A process for the preparation of a compound of formula (A 11)

wherein, R 3 is hydrogen; R 1 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined for formula (I), according to claim 1 , which comprises:

reacting a compound of formula (A7)

with a compound of formula R 8 N═C═S, wherein R 3 is hydrogen; R 1 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined for formula (I), according to claim 1 in the presence of dichloromethane (DCM) as a solvent to obtain the compound of formula (A 11); and optionally converting the resulting compound into a pharmaceutically acceptable salt.